28/04/2022, 10:47 Docplexus Alert Tadalafil for Treatment of Vascular Dementia Dr. Aayush Gandhi date_range FEB 2022 bookmark_border FOLLOW Recent research published in Alzheimer's & Dementia looked at whether tadalafil, a drug similar to sildenafil, may help persons with vascular dementia. The researchers ran a Phase II trial to see if tadalafil improves brain blood flow in older men and women who have Intracranial stenosis, which can lead to strokes and vascular dementia. Dementia is a growing global health problem, affecting 55 million people now and is expected to rise to 139 million by 2050. As fewer treatment choices are available to patients, the current study looked at whether repurposing an existing drug, tadalafil, to treat vascular dementia. Vascular dementia is a prevalent condition marked by the restricted blood supply to the brain. Sildenafil and vardenafil, medicines routinely used to enhance blood flow in erectile dysfunction and pulmonary hypertension, were found as viable candidates for preventing or delaying dementia in recent computational research. Tadalafil belongs to the same class of drugs as sildenafil https://www.docplexus.com/user/content/generic/57c5e905-2529-4873-b0ca-db953b6f9375 1/5 28/04/2022, 10:47 Docplexus and vardenafil, and the researchers believe that the process that boosts blood flow in other regions of the body may also apply in the brain and lessen dementia symptoms. The trial assessed a single dose of tadalafil to a placebo, measuring cerebral blood flow with an MRI-based technique called arterial spin labeling, which tracks blood flow without the use of radioactive tracers. The trial included 65 individuals who were randomized– 59 commenced the protocol, 55 completed it, and 53 had a complete set of usable central blood flow (CBF) data. There were no statistically significant variations in demographics between individuals who were randomly assigned and those who underwent the protocol. In this investigation, there was insufficient data to establish a significant difference in resting subcortical central blood flow between single dose tadalafil (20 mg) and the placebo. In small vessel disease, a drop in blood pressure was noted but this did not result in hypoperfusion. A tendency toward increased white matter hyperintensities perfusion implies that phosphodiesterase-5 (PDE5i) medication, maybe for a longer period, could be beneficial clinically. Reference: Pauls MMH, Binnie LR, Benjamin P, and et al. The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment. Alzheimers Dement. 2022 Feb 8. favorite_border chat_bubble_outline 0 visibility 2 23 share 2 Comments Add a comment Yes, the drug looks promising Can’t comment, more research is needed. Dr. Subhash Chandra Mukhe... Consultant at Nightingale Hospital,... https://www.docplexus.com/user/content/generic/57c5e905-2529-4873-b0ca-db953b6f9375 2/5 28/04/2022, 10:47 Docplexus Can’t comment, more research is needed. Reply Dr. Aayush Gandhi Family Medicine, Allergy & Immunology We are extremely grateful for your response Dr. Subhash Chandra Mukherjee . Wishing you a great day ahead. Happy Docplexing! Recommended Reading Solve This Urological Case date_range Jun 2017 Erectile Dysfunction date_range Dec 2014 Benign Prostatic Hyperplasia Medical Management date_range Dec 2017 Pulmonary hypertension date_range May 2015 New Treatment Strategies for Pulmonary Hypertension date_range Mar 2017 https://www.docplexus.com/user/content/generic/57c5e905-2529-4873-b0ca-db953b6f9375 3/5
